As reported on FierceBioTech, Biohaven closed out the holiday period with disappointing news: its investigational Kv7.2/7.3 potassium‑channel modulator, BHV‑7000, did not demonstrate efficacy in a
Editor’s Note: Patient Worthy is proud to share this story from our friends at Elephants & Tea. To see the story in its original format,
Menopause-related insomnia affects approximately one in four women during the menopausal transition, yet it remains significantly underdiagnosed and undertreated. A new analysis published in Maturitas
As reported by NewsWise, new clinical study led by investigators at the University of North Carolina at Chapel Hill is offering rare hope for families
Axsome Therapeutics has reached a significant regulatory milestone with the US Food and Drug Administration’s acceptance of a supplemental New Drug Application (NDA) for AXS-05
As reported by Forbes, the U.S. Food and Drug Administration has granted approval to Flow Neuroscience for the first prescription brain stimulation device designed for
Soleno Therapeutics has achieved a significant milestone in the treatment of a rare genetic disorder, announcing the publication of pivotal clinical study results for VYKAT™
Editor’s Note: Patient Worthy is proud to share this caregiver story submitted to us by Missy Williams. Nine years later, I can still picture the
ImmunityBio’s latest clinical findings reveal a significant development in the ongoing battle against non-muscle-invasive bladder cancer, with three-year follow-up data suggesting that combining Anktiva with
Editor’s Note: Patient Worthy is proud to share this article, originally written by Katie Tat, from our friends at Elephants & Tea. To see the
As reported on Science Daily, a recent clinical study suggests that a traditional Chinese herbal remedy may offer a unique advantage in treating major depressive
FibroBiologics Inc, a clinical-stage biotechnology company, has announced a significant breakthrough in regenerative medicine by submitting a Phase 1/2 Investigational New Drug (IND) application to
Editor’s Note: Patient Worthy is honored to share Michelle Patidar’s patient story, provided to us by our friends at Elephants & Tea. To see the
My chronic health journey is super complicated. When I first started experiencing my symptoms I wouldn’t tell anyone what I was feeling. I would wake
When pharmaceutical companies develop medications for serious diseases like prostate cancer, few anticipate how those treatments might transform care for entirely different patient populations. Yet,
Altimmune has released updated 48-week results from its phase 2 trial of pemvidutide, a GLP-1/glucagon dual receptor agonist being developed for metabolic dysfunction-associated steatohepatitis (MASH),
CRISPR Therapeutics has announced encouraging early results for zugocaptagene geleucel (zugo-cel), its investigational allogeneic CAR T therapy targeting CD19, in both autoimmune diseases and hematologic
As reported on PharmaBiz, Amneal Pharmaceuticals, in collaboration with mAbxience, has received U.S. Food and Drug Administration (FDA) approval for two denosumab biosimilars: Boncresa (referencing
Rheumatoid Arthritis Awareness Day is observed on February 2 each year to spread awareness about this chronic autoimmune disease.
RA causes joint pain, swelling, and can also affect organs such as the heart and lungs.
Established by the Rheumatoid Patient Foundation in 2013, this day highlights the importance of early diagnosis and better understanding of RA.
Let’s support those living with RA by learning the symptoms and sharing awareness.
#RAAwareness #RheumatoidArthritisAwarenessDay #PatientWorthy
#stargartdisease #clinicaltrial @FoundationFightingBlindnessA new clinical trial is now enrolling for individuals with ABCA4-related Stargardt disease.
The CELESTE Study, sponsored by AAVantgarde Bio, is a first-in-human Phase 1/2 clinical trial evaluating an investigational gene therapy designed to address the genetic cause of Stargardt disease—with the goal of slowing or halting vision loss.
The study is recruiting eligible participants ages 8–55 at select sites in the U.S., U.K., and Europe.
Learn more by contacting: [email protected], or please visit ClinicalTrials.gov
Image Description: Dark blue background with the Foundation Fighting Blindness logo at the top, with text below in green that says "Partner News." Below that is the text "New clinical trial for ABCA4-related Stargardt disease," followed by the AAVantgarde Bio logo.
youtu.be/IamF3rCdWuQ @TomSeaman
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
